Auteurs
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Auteurs » - entrée « Keiko Yoshimoto »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Keiko Yamauchi-Takihara < Keiko Yoshimoto < Keishi Fujio  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000763 (2018) Shinya Tasaki [Japon] ; Katsuya Suzuki [Japon] ; Yoshiaki Kassai [Japon] ; Masaru Takeshita [Japon] ; Atsuko Murota [Japon] ; Yasushi Kondo [Japon] ; Tatsuya Ando [Japon] ; Yusuke Nakayama [Japon] ; Yuumi Okuzono [Japon] ; Maiko Takiguchi [Japon] ; Rina Kurisu [Japon] ; Takahiro Miyazaki [Japon] ; Keiko Yoshimoto [Japon] ; Hidekata Yasuoka [Japon] ; Kunihiro Yamaoka [Japon] ; Rimpei Morita [Japon] ; Akihiko Yoshimura [Japon] ; Hiroyoshi Toyoshiba [Japon] ; Tsutomu Takeuchi [Japon]Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission.
000C45 (2017) Shuntaro Saito [Japon] ; Katsuya Suzuki [Japon] ; Keiko Yoshimoto [Japon] ; Yuko Kaneko [Japon] ; Yoshihiro Matsumoto [Japon] ; Kunihiro Yamaoka [Japon] ; Tsutomu Takeuchi [Japon]A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
000E91 (2016) Keisuke Izumi ; Yuko Kaneko ; Misato Hashizume ; Keiko Yoshimoto ; Tsutomu TakeuchiCorrection: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
001051 (2015) Jun Kikuchi [Japon] ; Misato Hashizume [Japon] ; Yuko Kaneko [Japon] ; Keiko Yoshimoto [Japon] ; Naoshi Nishina [Japon] ; Tsutomu Takeuchi [Japon]Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
001188 (2015) Keisuke Izumi [Japon] ; Yuko Kaneko [Japon] ; Misato Hashizume [Japon] ; Keiko Yoshimoto [Japon] ; Tsutomu Takeuchi [Japon]Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
001412 (2014) Naoshi Nishina [Japon] ; Jun Kikuchi ; Misato Hashizume ; Keiko Yoshimoto ; Hideto Kameda ; Tsutomu TakeuchiBaseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i -k "Keiko Yoshimoto" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i  \
                -Sk "Keiko Yoshimoto" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Keiko Yoshimoto
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021